List view / Grid view
7 September 2015 | By Victoria White
Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
4 September 2015 | By Victoria White
Breakthrough therapy designation has been granted to ACE910 for the prophylactic treatment of people with haemophilia A with factor VIII inhibitors...
4 September 2015 | By Victoria White
Allergan is to acquire AqueSys for a $300 million upfront payment and milestone payments related to AqueSys' lead development programmes, including XEN45...
4 September 2015 | By Victoria White
While generic acute coronary syndrome (ACS) drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60% of the total market by 2019...
3 September 2015 | By Victoria White
The extent of data breaches in the pharmaceutical sector has been revealed by a survey that shows 60% have lost important data...
3 September 2015 | By Victoria White
PHE is calling for pregnant women to take up the whooping cough vaccine as surveillance figures confirm that whooping cough activity remains at raised levels in England...
3 September 2015 | By Victoria White
NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis...
3 September 2015 | By Victoria White
If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously for the treatment of SHPT in patients with chronic kidney disease...
3 September 2015 | By Victoria White
Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion...
3 September 2015 | By Victoria White
The FDA has granted Fast Track designation to iclaprim to treat acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia...
2 September 2015 | By Victoria White
Teflaro is now approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia...
2 September 2015 | By Victoria White
ABSORB Japan, a trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb heart stent to Xience, has produced positive results...
